Clinical Trials Action Group (Ctag), Pharmaceutical Industry Working Group
Recommendation on strengthening Australia’s clinical trials contribution and competitiveness
As an independent not-for-profit medical research institute that manages a major clinical trials research program, the key message of this recommendation is that any “Roadmap for Clinical Trials” must ensure that the health value of the clinical trials conducted in Australia is given at least as much emphasis as the financial value.
Our recommendations emphasised the need for Government initiatives and funding aimed at both increasing and diversifying clinical trial activity in areas of national strategic importance. We also recommend the adoption of a Government financing scheme, similar to that deployed to support the development of venture capital investment industry in Australia. Submitted February 2010.